Can Wegovy Cause Pancreatitis? What the Data Shows

At a glance

• Wegovy label status / acute pancreatitis is a warned serious adverse reaction [1]
• Label action if suspected / discontinue Wegovy and initiate appropriate management [1]
• Adult trial data / acute pancreatitis confirmed in 4 Wegovy-treated patients (0.2 per 100 patient-years) vs 1 on placebo [1]
• Label description / includes fatal and non-fatal hemorrhagic or necrotizing pancreatitis [1]
• Symptoms named in the label / persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1]
• Adult weight-trial gallbladder rates / cholelithiasis 1.6% vs 0.7%; cholecystitis 0.6% vs 0.2% [1]
• Common GI effects in adults / nausea 44% vs 16%, diarrhea 30% vs 16%, vomiting 24% vs 6%, constipation 24% vs 11% [1]
• Discontinuation for adverse reactions / 6.8% with Wegovy 2.4 mg vs 3.2% with placebo [1]
• Contraindications / personal or family history of MTC or MEN 2; prior serious hypersensitivity [1]

Does Wegovy cause pancreatitis?

The Wegovy prescribing information lists acute pancreatitis as a serious adverse reaction and warns that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including Wegovy [1].

What does the label say to do if pancreatitis is suspected?

The label says to observe patients carefully after starting Wegovy for signs and symptoms of acute pancreatitis. Those symptoms may include persistent or severe abdominal pain, sometimes radiating to the back, and may or may not be accompanied by nausea or vomiting [1]. If pancreatitis is suspected, the label says to discontinue Wegovy and initiate appropriate management [1].

Is a history of pancreatitis a contraindication to Wegovy?

The Wegovy label's contraindications are a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to semaglutide or an excipient [1]. A history of pancreatitis is not one of the listed contraindications, and the acute pancreatitis warning applies to patients who start Wegovy [1].

What other pancreatitis risk factors matter?

A 2021 review describes hypertriglyceridemia as a significant contributor to pancreatitis risk [3], and a 2024 trial in severe hypertriglyceridemia (fasting triglycerides 500 to 4000 mg/dL) describes that condition as conferring increased risk of acute pancreatitis [2].

What about gallbladder disease and GI side effects?

Wegovy carries a separate warning for acute gallbladder disease. In adult weight-reduction trials, cholelithiasis was reported by 1.6% of Wegovy injection patients versus 0.7% on placebo, and cholecystitis by 0.6% versus 0.2% [1]. The label says acute gallbladder disease was more frequent with Wegovy even after accounting for weight loss [1].

Common GI reactions are also listed in the label: nausea 44% vs 16%, diarrhea 30% vs 16%, vomiting 24% vs 6%, and constipation 24% vs 11% [1]. The pancreatitis warning specifically names persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1].

What else does the label list alongside pancreatitis?

The label lists acute pancreatitis among the serious adverse reactions described in the prescribing information, along with acute gallbladder disease, hypoglycemia, acute kidney injury from volume depletion, and severe gastrointestinal reactions [1].

Frequently asked questions

›Does Wegovy cause pancreatitis?

Wegovy's label warns that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists including Wegovy, and says to discontinue Wegovy if pancreatitis is suspected. In its adult trials, acute pancreatitis was confirmed in 4 Wegovy-treated patients versus 1 on placebo [1].

›What does the label say to do if pancreatitis is suspected?

The Wegovy label says to discontinue Wegovy and initiate appropriate management if pancreatitis is suspected [1]. It also says to observe patients for persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1].

›Is prior pancreatitis a contraindication to Wegovy?

The listed contraindications are a personal or family history of medullary thyroid carcinoma or MEN 2, and prior serious hypersensitivity to semaglutide or an excipient [1]. Prior pancreatitis is not listed as a contraindication, and the acute pancreatitis warning applies [1].

›Does Wegovy raise gallbladder disease risk?

Yes. In adult weight-reduction trials, cholelithiasis was reported by 1.6% of Wegovy injection patients versus 0.7% on placebo, and cholecystitis by 0.6% versus 0.2% [1]. The label says acute gallbladder disease was more frequent with Wegovy even after accounting for weight loss [1].

›What are the common GI side effects of Wegovy?

In adult weight-management trials, nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, and constipation in 24% versus 11% [1]. Overall, 6.8% of patients on Wegovy 2.4 mg discontinued for adverse reactions versus 3.2% on placebo [1].

References

1. U.S. National Library of Medicine, DailyMed. Wegovy injection and tablets prescribing information. Wegovy injection and tablets label
2. Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024;9(7):620-630. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial
3. Hernandez P, Passi N, Modarressi T, Kulkarni V, Soni M, Burke F, et al. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. Curr Atheroscler Rep. 2021;23(11):72. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis